155 Bovet Road
Suite 660
Welcome to Scrip
Create an account to read this article
Already a subscriber?
Itero Biopharmaceuticals Inc.
The biosimilars business isn't necessarily a logical niche for a small start-up company. The industry's many attendant challenges-clinical, manufacturing, and regulatory-are more the domain of the established generics companies, big biotechs, and more recently Big Pharmas, which have the capital and infrastructure to handle them. Try telling that to Itero Biopharmaceuticals, which plans to develop follow-on therapeutic proteins and antibodies en route to creating its own biologics pipeline. In order to compete in this multibillion-dollar market, Itero intends to forge and leverage strategic partnerships in far-flung corners of the world.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.
• By
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
• By
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.